Обоснование выбора лекарственной терапии при хронической обструктивной болезни легких

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop repot Updated 2008. www. goldcopd.com Last accessed: June 2008.
2. Postma DS, Calverley P Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34 (1): 10–2.
3. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–03.
4. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
5. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in Combination with Placebo, Salmeterol or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. Ann Intern Med 2007; 146: 545–55.
6. Wedzicha JA, Calverley PMA, Seemungal TA et al. The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
7. Tashkin DP, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543–54.
8. Хроническая обструктивная болезнь легких. (Федеральная программа). Практическое руководство для врачей. Под ред. А.Г.Чучалина. М., 2004.
9. Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М.: Изд-ий дом «Атмосфера», 2008.
10. van Noord JA, Aumann J-L. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
11. Welte T, Hartman L, Polanowski T et al. Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients. Am J Respir Crit Care Med 2009; 179: A6188.
12. Welte T, Miravitlles M, Peterson S et al. Budesonide/formoterol added to tiotropium improves the management of COPD patients. Am J Respir Crit Care Med 2009; 179: A6192.
13. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34 (1): 13–6.
14. Garbe E, LeLorier J, Boivin JF et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–7.
15. Hubbard RB, Smith CJ, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6.
16. Suissa S, Baltzan M, Kremer R et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8.
17. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14.
18. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–43.
19. Ernst P, Baltzan M, Deschenes J et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–74.
20. Ernst P, Gonzalez AV, Brassard P et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–6.
21. Keatings VM, Jatakanon A, Worsdell YM et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–8.
22. Culpitt SV, Maziak W, Loukidis S et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635–9.
23. Loppow D, Schleiss MB, Kanniess F et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001; 95: 115–21.
24. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 3.
25. Hattotuwa KL, Gizycki MJ, Ansari TW et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–6.
26. Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938–43.
27. Ito K, Ito M, Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967–76.
28. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol 2008; [Epub Ahead of Print PMD: 18817512].
29. Rabe KF, Timmer W, Sagkriotis A et al. Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. CHEST 2008; 134: 255–62.
30. Troosters T, Kesten S, Burkhart D, Celli B et al. Effectiveness of Tiotropium as First Maintenance Drug in Patients with COPD. Secondary Analysis of the UPLIFT Trial. Am J Respir Crit Care Med 2009; 179: A2467.
31. Лещенко И.В. Ключевые вопросы ранней терапии хронической обструктивной болезни легких. Consilium Medicum 2008; 10 (10): 46–50.